Argenica Therapeutics Limited (ASX:AGN)

Market Cap	100.83M
Revenue (ttm)	3.08M
Net Income (ttm)	-5.26M
Shares Out	128.45M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	226,164
Average Volume	107,023
Open	0.7200
Previous Close	0.7850
Day's Range	0.6850 - 0.7350
52-Week Range	0.5950 - 0.9850
Beta	0.79
RSI	53.68
Earnings Date	May 19, 2025

About Argenica Therapeutics

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is headquartered in Nedlands, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AGN

Financial Performance

In 2024, Argenica Therapeutics's revenue was 2.60 million, an increase of 48.46% compared to the previous year's 1.75 million. Losses were -5.48 million, 13.8% more than in 2023.